# US 2021/0340547 A1 · Fibrotic treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340547 A1
- Document ID: US20210340547A1
- Status: Published application
- Kind: A1
- Application number: 17/365,260
- Filed: 2021-07-01
- Published: 2021-11-04
- Earliest claimed: 2015-07-30
- Assignees: Monash University
- Applicants: Monash University
- Inventors: Siew Yeen Chai; Robert Widdop; Tracey Gaspari; Huey Wen Lee
- Web page: https://patentgrep.com/patent/US20210340547A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/351: not condensed with another ring
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.

## Claims

### Claim 1

A method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP) thereby treating fibrosis.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the individual is identified as having fibrosis.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or 2, wherein the method reduces progression of at least one clinically or biochemically observable characteristic of fibrosis, thereby treating fibrosis.

### Claim 4 (depends on 1, 2)

A method according to claim 1 or 2, wherein the method reverses at least one clinically or biochemically observable characteristic of fibrosis, thereby treating fibrosis.

### Claim 5 (depends on 3, 4)

A method according to claim 3 or 4, wherein the clinically or biochemically observable characteristic comprises any one of organ dysfunction, scarring, alteration of normal extracellular matrix balance, increase in collagen deposition, differentiation of fibroblasts to myofibroblasts, reduction in the level of matrix metalloproteinases, increase in the level of tissue Inhibitors of matrix metalloproteinases, increased levels of either N-terminal or C-terminal propeptide of type I procollagen (PINP or PICP), decreased levels of C-terminal telopeptide of Type I Collagen (CTP or CITP), increased collagen deposition or impaired cardiac function measured by various noninvasive imaging techniques, and impaired renal function measured by increased proteinurea and albuminurea, decreased glomerular filtration rate, doubling of plasma creatinine levels.

### Claim 6 (depends on 5)

A method according to claim 5, wherein collagen is a precursor or mature forms of collagen al Type 1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1 to 6, wherein the fibrosis is age-induced.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1 to 6, wherein the fibrosis is stress-induced or injury-induced.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the fibrosis is associated with hypertensive heart disease, hypertensive cardiomyopathy or heart failure, or nephropathy with or without associated diabetes, or other stress-induced or injury-induced cardiovascular sequelae that may involve a fibrotic response, with or without underlying cardiovascular disease.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method according to any one of claims 1 to 9, further comprising the step of identifying an individual having fibrosis.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method according to any one of claims 1 to 10, wherein the fibrosis is selected from the group consisting of cardiac fibrosis, liver fibrosis, kidney fibrosis, vascular fibrosis, lung fibrosis and dermal fibrosis.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the fibrosis is cardiac fibrosis.

### Claim 13 (depends on 11)

A method according to claim 11, wherein the fibrosis is kidney fibrosis.

### Claim 14 (depends on 11)

A method according to claim 11, wherein the fibrosis is liver fibrosis.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the fibrosis is non-alcoholic steatohepatitis (NASH).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method according to any one of claims 1 to 15, wherein the inhibitor of IRAP directly or indirectly inhibits the enzymatic activity of IRAP.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method according to any one of claims 1 to 16, wherein the inhibitor of IRAP directly inhibits the enzymatic activity of IRAP.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the inhibitor binds to IRAP.

### Claim 19 (depends on 17, 18)

A method according to claim 17 or claim 18, wherein the inhibitor binds to the active site of IRAP.

### Claim 20 (depends on 17, 18)

A method according to claim 17 or claim 18, wherein the inhibitor of IRAP competes with a substrate of IRAP for binding to IRAP.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method according to any one of claims 1 to 20, wherein the inhibitor of IRAP exhibits a Ki value of less than 1 mM, preferably less than 100 μM, more preferably less than 10 μM, as determined by an assay of aminopeptidase activity or substrate degradation.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the assay of amino peptidase activity comprises hydrolysis of the synthetic substrate L-Leucine 7-amido-4-methyl coumarin hydrochloride (Leu-MCA) monitored by release of the fluorogenic product MCA.

### Claim 23 (depends on 22)

A method according to claim 22, wherein the assay of substrate degradation is degradation of the peptide substrates CYFQNCPRG or YGGFL.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method according to any one of claims 1 to 23, wherein the inhibitor is selected from the group consisting of a small molecule, an antibody and a peptide.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method according to any one of claims 1 to 15, wherein the inhibitor is an interfering RNA.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 1 to 24, wherein the inhibitor has a structure according to Formula (I):
wherein
A is aryl, heteroaryl carbocyclyl or heterocyclyl, each of which may be optionally substituted, when R1 is NHCOR8;
or quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridyl, phthalazinyl or pteridinyl, each of which may be optionally substituted, when R1 is NR7R8, NHCOR8, N(COR8)2, N(COR7)(COR8), N═CHOR8 or N═CHR8;
X is O, NR′ or S, wherein R′ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted acyl, optionally substituted heteroaryl, optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R7 and R8 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, or R7 and R8, together with the nitrogen atom to which they are attached form a 3-8-membered ring which may be optionally substituted;
R2 is CN, CO2R9, C(O)O(O)R9, C(O)R9 or C(O)NR9R10 wherein R9 and R10 are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, each of which may be optionally substituted, and hydrogen; or R9 and R10 together with the nitrogen atom to which they are attached, form a 3-8-membered ring which may be optionally substituted;
R3-R6 are independently selected from hydrogen, halo, nitro, cyano alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, carbocyclyl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, alkynyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, amino, acyl, acyloxy, carboxy, carboxyester, methylenedioxy, amido, thio, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, carbocyclylthio, acylthio and azido, each of which may be optionally substituted where appropriate, or any two adjacent R3—R6, together with the atoms to which they are attached, form a 3-8-membered ring which may be optionally substituted; and
Y is hydrogen or C1-10alkyl,
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 27 (depends on 26)

A method according to claim 26, wherein A is optionally substituted heteroaryl when R1 is NHCOR8.

### Claim 28 (depends on 26, 27)

A method according to claim 26 or 27, wherein A is pyridinyl.

### Claim 29 (depends on 26, 27, 28)

A method according to any one of claims 26 to 28, wherein X is O.

### Claim 30 (depends on 26, 27, 28, 29)

A method according to any one of claims 26 to 29, wherein R2 is CO2R9.

### Claim 31 (depends on 26, 27, 28, 29, 30)

A method according to any one of claims 26 to 30, wherein R5 is hydroxyl.

### Claim 32 (depends on 26, 27, 28, 29, 30, 31)

A method according to any one of claims 26 to 31, wherein the inhibitor has the structure:

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 1 to 24, wherein the inhibitor has a structure according to Formula (II):
wherein
A is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, each of which may be optionally substituted;
RA and RB are independently selected from hydrogen, alkyl and acyl;
R1 is selected from CN or CO2RC;
R2 is selected from CO2RC and acyl;
R3 is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, each of which may be optionally substituted; or
R2 and R3 together form a 5-6-membered saturated keto-carbocyclic ring:
wherein n is 1 or 2;
and which ring may be optionally substituted one or more times by C1-6alkyl; or
R2 and R3 together form a 5-membered lactone ring (a) or a 6-membered lactone ring (b)
wherein is an optional double bond and R′ is alkyl.
RC is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, each of which may be optionally substituted;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 34 (depends on 33)

A method according to claim 33, wherein A is optionally substituted aryl.

### Claim 35 (depends on 33, 34)

A method according to claim 33 or 34, wherein A is aryl substituted with —COOH, or a salt, ester or prodrug thereof.

### Claim 36 (depends on 35)

A method according to claim 35, wherein A is aryl substituted with —CO2−NH4+.

### Claim 37 (depends on 33, 34, 35, 36)

A method according to any one of claims 33 to 36, wherein R1 is CN.

### Claim 38 (depends on 33, 34, 35, 36, 37)

A method according to any one of claims 33 to 37, wherein R2 is acyl.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

A method according to any one of claims 33 to 38, wherein the inhibitor has the structure:

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 1 to 24, wherein the inhibitor has a structure according to Formula (III):
wherein
R1 is H or CH2COOH; and
n is 0 or 1; and
m is 1 or 2; and
W is CH or N;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 41 (depends on 40)

A method according to claim 40, wherein the inhibitor has the structure:

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 1 to 24, wherein the inhibitor has a structure according to any one of the following sequences:
Val-Tyr-Ile-His-Pro-Phe,
c[Cys-Tyr-Cys]-His-Pro-Phe,
and
c[Hcy-Tyr-Hcy]-His-Pro-Phe.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 1 to 24, wherein the inhibitor has a structure according to:
